Article Text

PDF
Rivastigmine three times daily improves cognition and response in Alzheimer’s disease

Statistics from Altmetric.com

What is the efficacy and safety of rapidly titrated rivastigmine compared to placebo, when administered twice or three times daily in people with mild to moderate Alzheimer’s disease?

Feldman HH, Lane R. Rivastigmine: a placebo-controlled trial of BID and TID regimens in patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2007 Mar 12; [Epub ahead of print].

METHODS

Embedded ImageDesign:

Randomised controlled trial.

Embedded ImageAllocation:

Unclear.

Embedded ImageBlinding:

Double blinded.

Embedded ImageFollow-up period:

Twenty six weeks (treatment period only).

Embedded ImageSetting:

Thirty seven research centres, Australia, Canada, Ireland, Italy, South Africa, and the UK; time period not stated.

Embedded ImagePatients:

678 community dwelling adults aged ⩾50 years with Alzheimer’s disease (AD; meeting both DSM-IV criteria and criteria for “probable” Alzheimer’s disease of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s disease and Related Disorders Association), and who had a Mini-Mental State Examination score of 10–26. Exclusions: severe obstructive pulmonary disease, cardiac disease, or other life threatening condition; use of anticholinergic drugs, insulin, psychotropics (with some exceptions), supplements containing acetylcholine precursors, or supposed memory enhancers.

Embedded ImageIntervention:

Rivastigmine …

Dr Howard Feldman, S192–2211 Westbrook Mall, Division of Neurology, Department of Medicine, University of British Columbia Hospital, Vancouver, BC, Canada, V6T 2B5

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.